Starpharma

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Starpharma had revenue of €736.63k and net profit of -€5.34m

(EUR)	June 2026	YoY
Revenue	736.63k	-
Gross profit	214.7k	-
Net profit	-5.34m	-
EBITDA	-8.94m	-

Fundamentals

Metric	Value
Market capitalization	€140.18m
Number of shares	482.91m
52-week high/low	€0.53 - €0.19
Dividends	No
Beta	0.77
P/E ratio	-24.85
PEG ratio	0.18
P/B ratio	13.33
P/S ratio	17.03

Company profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.